MedTrace Logo

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2026-04-14

No results posted yet for this study

Summary

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Conditions

Interventions

DRUG

Relacorilant 150 mg once daily (QD)

Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

DRUG

Nab-paclitaxel 80 mg/m^2

Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

DRUG

Bevacizumab 10 mg/kg

Bevacizumab is administered as IV infusion on Days 1 and 15.

Sponsors & Collaborators

  • Corcept Therapeutics

    lead INDUSTRY

Principal Investigators

  • Sachin Pai, MD, MS · Corcept Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-11
Primary Completion
2026-08-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Italy
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06906341 on ClinicalTrials.gov